Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

被引：56

作者：

Cho, B. C. ^{[1
]}

Felip, E. ^{[2
,3
]}

Spira, A. I. ^{[4
]}

Girard, N. ^{[5
,6
]}

Lee, J. S. ^{[7
]}

Lee, S. H. ^{[8
]}

Ostapenko, Y. V. ^{[9
]}

Danchaivijitr, P. ^{[10
]}

Liu, B. ^{[11
]}

Alip, A. ^{[12
]}

Korbenfeld, E. P. ^{[13
]}

Dias, J. ^{[14
]}

Sun, T. ^{[15
]}

Martinez, M.

Bauml, J. M. ^{[16
]}

Shreeve, M. ^{[17
]}

Sethi, S. ^{[16
]}

Knoblauch, R. E. ^{[16
]}

Hayashi, H. ^{[18
]}

Lu, S. ^{[19
]}

机构：

[1] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[2] Vall Hebron Univ Hosp, Barcelona, Spain

[3] Vall Hebron Inst Oncol, Barcelona, Spain

[4] Virginia Canc Specialists, Fairfax, VA USA

[5] Inst Thorax Curie Montsouris, Inst Curie, Paris, France

[6] UVSQ, Univ Paris Saclay, Versailles, France

[7] Seoul Natl Univ Bundang Hosp, Seongnam, South Korea

[8] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[9] Natl Canc Inst, Kiev, Ukraine

[10] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand

[11] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[12] Univ Malaya Med Ctr, Kuala Lumpur, Malaysia

[13] Hosp Britanico Buenos Aires, Buenos Aires, DF, Argentina

[14] Barretos Canc Hosp, Barretos, Brazil

[15] Janssen R&D, Raritan, NJ USA

[16] Janssen R&D, Spring House, PA USA

[17] Janssen R&D, San Diego, CA USA

[18] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan

[19] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.062

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA14

引用

页码：S1306 / S1306

页数：1